Are compounded bioidentical hormones safer?
Written and medically reviewed by Zahraa Sater, M.D., M.P.H.
Reviewed August 12, 2026 · Next review due August 12, 2028
Short answer
No. Compounded bioidentical hormones are not tested or approved by the FDA, which states it does not verify the safety, effectiveness or quality of compounded drugs before they are marketed. The 2020 National Academies report found insufficient evidence for their safety and effectiveness and recommended restricting use. FDA approved estradiol and micronised progesterone are already bioidentical.
Compounded bioidentical hormones are not safer, and the word bioidentical is doing more marketing work than clinical work. Bioidentical means chemically identical to the hormones the body makes. Several FDA approved products already meet that definition, including estradiol patches, gels and sprays, and micronised progesterone capsules. The difference between those and a compounded preparation is not the molecule. It is the testing, the manufacturing standards and the regulatory oversight.
What the FDA actually says
The FDA states that compounded drugs are not FDA approved and that it does not verify the safety, effectiveness or quality of compounded drugs before they are marketed. It also warns that poor compounding practices can produce serious quality problems, including contamination or a product containing too much or too little active ingredient. Compounded hormones do not carry the standard estrogen label warnings, and their absence is sometimes presented as evidence of greater safety. It is not. It reflects the absence of a reviewed label.
What the National Academies found
In 2020 the National Academies of Sciences, Engineering, and Medicine published a review of compounded bioidentical hormone therapy commissioned by the FDA. The committee found insufficient evidence to support the safety and effectiveness of these preparations and recommended that prescribers restrict their use to specific medical circumstances rather than prescribe them routinely. Those circumstances are narrow: an allergy to an ingredient in an approved product, or a dose or route that is genuinely unavailable commercially.
Comparing the two options
| Feature | FDA approved hormone therapy | Compounded preparation |
|---|---|---|
| Bioidentical molecules available | Yes, estradiol and micronised progesterone | Yes |
| Tested for safety and effectiveness | Yes, before approval | No |
| Dose verified batch to batch | Yes | Not verified by the FDA |
| Standard label and warnings | Yes | No |
| Usually covered by insurance | Often | Usually paid out of pocket |
Two further practices deserve caution. Saliva hormone testing used to customise compounded doses is not a validated way to guide hormone dosing. Pellets implanted under the skin cannot be removed if levels run high, and the 2019 global consensus on testosterone in women advises against any preparation producing supraphysiologic concentrations, naming pellets specifically. Ask whether an FDA approved product exists in the same molecule, dose and route before agreeing to a compounded one, because in most cases it does.
The clinical detail
Approved bioidentical options include transdermal estradiol at 0.025 to 0.1 mg per day, estradiol gels and sprays, oral estradiol, vaginal estradiol tablets, creams and rings, oral micronised progesterone, and a combined estradiol with progesterone capsule. Custom compounded combinations of estriol, estrone and estradiol, and preparations dosed against saliva or serum hormone targets, have no outcome data supporting either regimen selection or endometrial safety. Endometrial protection is the specific concern with compounded progesterone creams, since transdermal progesterone does not reliably produce serum concentrations sufficient to oppose estrogen at the endometrium.
Written and medically reviewed by Zahraa Sater, M.D., M.P.H.
Reviewed August 12, 2026 · Next review due August 12, 2028
Sources
- Compounding and the FDA: Questions and Answers. U.S. Food and Drug Administration
- The Clinical Utility of Compounded Bioidentical Hormone Therapy: A Review of Safety, Effectiveness, and Use. National Academies of Sciences, Engineering, and Medicine. doi:10.17226/25791
- Position Statements, including the 2022 Hormone Therapy and 2023 Nonhormone Therapy statements. The Menopause Society. PMID 35797481
- Estradiol Transdermal System, full prescribing information. DailyMed, U.S. National Library of Medicine
- Global Consensus Position Statement on the Use of Testosterone Therapy for Women. Journal of Clinical Endocrinology and Metabolism. PMID 31498871
This library is educational and is not individual medical advice. Read our Editorial and Medical Review Policy.